98th Annual Meeting DOG 2000

P 80

Immunosuppressive therapy with Mycophenolate Mofetil (CellCeptâ ) for ocular diseases associated with atopic dermatitis

A. Soares- Wulf1, R. Krüger1, J. Zurdel1, K. Neuber2, K. Engelmann1

Introduction: In atopic dermatitis the globe can be affected as well, e.g. in eczematous lesions of the lid, this may cause severe keratopathy. Immunosuppressive therapy in these cases is inevitable, namely following keratoplasty to reduce the risk of graft rejection. In an attempt to optimize therapy we have investigated Mycophenolate Mofetil (MMF) for effectiveness and side effects.

Methods: 6 patients (age 27 to 55 years) have been treated with MMF. In 3 out of 6 patients keratoplasty with consecutive immunosuppression with MMF was performed. 2 patients were treated preceeding keratoplasty for persistant corneal ulcer, 1 patient for progressive conjuntival metaplasia connected to atopic dermatitis in combination with other immunosuppressants.

Results: All 3 patients who did not yet undergo surgery showed improvement of their pathologic ocular condition as well as of stigmata of atopic dermatitis. No graft rejection was noted in the follow up of 3 patients who underwent keratoplasty ever since. One out of 6 patients complained of fatigue, 2 patients noted prolonged periods of headaches.

Conclusion: MMF may be useful as a new immunosuppressant with relatively few side effects. It may be able to prevent graft rejection following keratoplasty as well as to treat corneal ulcer and lid eczema connected to severe atopic dermatitis.

1Universitäts-Augenklinik, Martinistr. 52 D-20246 Hamburg. Germany
Universitäts- Hautklinik , Martinistr.52 D-20246 Hamburg, Germany